CA2490857C - Particulate therapeutic agent delivery device and method - Google Patents

Particulate therapeutic agent delivery device and method Download PDF

Info

Publication number
CA2490857C
CA2490857C CA2490857A CA2490857A CA2490857C CA 2490857 C CA2490857 C CA 2490857C CA 2490857 A CA2490857 A CA 2490857A CA 2490857 A CA2490857 A CA 2490857A CA 2490857 C CA2490857 C CA 2490857C
Authority
CA
Canada
Prior art keywords
gas
delivery device
therapeutic agent
respiratory
channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2490857A
Other languages
French (fr)
Other versions
CA2490857A1 (en
Inventor
Bradley P. Fuhrman
Mark S. Dowhy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of State University of New York
Original Assignee
Research Foundation of State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of State University of New York filed Critical Research Foundation of State University of New York
Publication of CA2490857A1 publication Critical patent/CA2490857A1/en
Application granted granted Critical
Publication of CA2490857C publication Critical patent/CA2490857C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/22—Carbon dioxide-absorbing devices ; Other means for removing carbon dioxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/01—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes specially adapted for anaesthetising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
    • A61M16/0883—Circuit type
    • A61M16/0891—Closed circuit, e.g. for anaesthesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/104—Preparation of respiratory gases or vapours specially adapted for anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes

Abstract

A particulate therapeutic agent delivery device (10) and method are disclosed. In an embodiment of the device there is a respiratory-gas channel (13) having a patient end (16) to which a patient may be pneumatically connected, a particulate-~therapeutic-agent channel (19) in pneumatic communication with the respiratory-gas channel, a scrubber housing (22) in pneumatic communication with the respiratory-gas channel, the scrubber housing having an expired-gas orifice (25) for receiving expired gas from the respiratory-gas-channel, and a scrubber material (26) situated within the housing so as to receive expired gas via the expired-gas orifice and remove carbon dioxide from the expired gas to provide treated gas, and situated so as to provide the treated gas to the respiratory-gas channel.

Description

PARTICULATE THERAPEUTIC AGENT DELIVERY DEVICE AND METHOD
Field of the Invention [0002] The present invention relates to methods and devices for delivering therapeutic agents to a patient's lungs.

Background of the Invention [0003] A particulate therapeutic agent may be carried by a carrier gas to a patient's lungs to treat the patient. For example, the carrier gas may be oxygen, and the therapeutic agent may be a liquid particulate or solid particulate. Such a mixture may be an aerosol. Such a mixture may be formed by nebulizing a liquid into the carrier gas. This method of administration may be advantageous when the therapeutic agent targets a specific site of action that is readily accessed by inspiration, or when pulmonary uptake of a therapeutic agent from the systemic circulation is suboptimal, or when systemic blood levels of a therapeutic agent are to be minimized. Examples of therapeutic agents that may be administered in this manner include bronchodilators, steroids, antibiotics, mucolytics, DNA lytic enzymes and genetic vectors for the treatment of lung disease. For example, antifungal and antiviral agents have been administered as aerosols. Further, chemotherapeutic agents for pulmonary malignancy and a host of pulmonary therapies having potential systemic toxicity or undesirable systemic side effects have been nebulized.
Additional therapies may include surfactant administration, perfluorocarbon delivery and liposomal drug administration.
[0004] The respiratory cycle of a human being is comprised of inspiration and expiration. Inspiration accounts for roughly '/4 of the respiratory cycle and expiration accounts for roughly 3/4 of the respiratory cycle. If a therapeutic agent is continuously moved past a patient's mouth, roughly 3/4 of the therapeutic agent may not be inspired, and therefore may be wasted. Furthermore, the therapeutic agent that is inspired maybe only partially taken up by the lung. For certain therapeutic agents, such as surfactant, more than 90% of inspired therapeutic agent may be subsequently expired (rather than retained in the lung) and thus lost in the expired air. This effect may be greatest when the therapeutic mixture has particulates that are especially small, as may be the case when the therapeutic agent has low surface tension (like surfactant and perfluorocarbon) or is a high density liquid (like perfluorocarbons).
[0005] One solution to these inefficiencies of dosing is to rebreathe expired gas, thus renewing the opportunity to take up the therapeutic agent rather than lose it to the environment after expiration. If a "single puff ' of the therapeutic agent could be repeatedly rebreathed, ultimate uptake could approach 100%. The same would be true for a "puff' followed by prolonged breath-holding. Repeated rebreathing of the same "puff', or prolonged breath holding may give rise to hypoxia, hypercarbia, discomfort, or may prolong the time required to deliver a requisite dose of the therapeutic agent.
Further, a high level of patient cooperation may be required. These problems complicate, if not prevent, use of these approaches to administer a therapeutic agent.
[0006] One solution to these problems involves intermittent dosing, in which the therapeutic agent is provided only during inspiration. This solution offers a significant gain in efficiency over continuous dosing, but is still limited in its usefulness by loss of unabsorbed therapeutic agent to the environment during expiration. This solution may be combined with breath-holding to further reduce expiratory losses, but the breath-holding approach may limit the rate of administration of the therapeutic agent and may require a high level of patient cooperation.

Summary of the Invention [0007] A particulate therapeutic agent delivery device according to the invention may include a respiratory-gas channel, a particulate-therapeutic-agent channel in pneumatic communication with the respiratory-gas channel, a scrubber housing in pneumatic communication with the respiratory-gas channel, and a scrubber material situated within the housing. The scrubber material may be used to remove CO2 from gas expired by a patient.

Gas that has been acted on by the scrubber material may be provided to the patient, so that the therapeutic agent is returned to the patient.
[0008] In a method according to the invention, a particulate therapeutic agent is provided to the respiratory system of a patient. A carbon dioxide scrubber may be provided in pneumatic communication with the respiratory system, and expired gas from the respiratory system may be provided to the scrubber. The expired gas may be passed through the scrubber to provide treated gas, which may be provided to the respiratory system. By such a method, particulate therapeutic agent which was present in the expired gas may be re-breathed by the patient.

Brief Description of the Drawings [0009] For a fuller understanding of the nature and objects of the invention, reference should be made to the following detailed description taken in conjunction with the accompanying drawings, in which:

Fig. 1 is a schematic diagram of a therapeutic agent delivery device according to an embodiment of the invention;
Fig. 2 is a is a schematic diagram of a therapeutic agent delivery device according to an embodiment of the invention;
Fig. 3 is a is a schematic diagram of a therapeutic agent delivery device according to an embodiment of the invention;
Fig. 4 is a is a schematic diagram of a therapeutic agent delivery device according to an embodiment of the invention;
Fig. 5 is a is a schematic diagram of a therapeutic agent delivery device according to-an embodiment of the invention;
Fig. 6 is a schematic diagram of a therapeutic agent delivery device according to an embodiment of the invention;
Fig. 7 is a is a schematic diagram of a therapeutic agent delivery device according to an embodiment of the invention; and Fig. 8 is a block diagram of a method according to the invention.

Detailed Description of the Invention [0010] Figure 1 is a schematic representation of an embodiment of a particulate therapeutic agent delivery device 10 according to the invention. The delivery device 10 may have a respiratory-gas channel 13 having a patient end 16 to which a patient may be pneumatically connected. The respiratory-gas channel 13 may include an endotracheal tube that may be inserted into the trachea of a patient.
[0011] The delivery device 10 may have a particulate-therapeutic-agent channel 19 in pneumatic communication with the respiratory-gas channel 13. An aerosol generator 28 may be provided in pneumatic communication with the particulate-therapeutic-agent channel 19.
The aerosol generator 28 may be a nebulizer, for example, a jet nebulizer or an ultrasonic nebulizer. The respiratory-gas channel 13 may include a mixing chamber 29, which may provide a location for the therapeutic agent to disperse and mix with respiratory gas.
[0012] A scrubber housing 22 may be in pneumatic communication with the respiratory-gas channel 13. The scrubber housing 22 may include an electrically conductive material so that an electric charge does not develop, and thereby cause therapeutic agent to collect on the scrubber housing 22. The scrubber housing 22 may have an expired-gas orifice 25, which may be used for receiving expired gas from the respiratory-gas-channel 13. A
scrubber material 26 may be disposed within the scrubber housing 22. A portion of the scrubber material 26 is illustrated in Figure 1. The scrubber material 26 may, be situated within the scrubber housing so as to receive expired gas via the expired-gas orifice 25. The scrubber material 26 may be soda lime. The scrubber material 26 may be situated so as to remove carbon dioxide from the expired gas to provide treated gas, and so as to provide the treated gas to the respiratory-gas channel 13.
[0013] Figure 1 shows that the particulate-therapeutic-agent channel 19 may be in pneumatic communication with an agent delivery location 31 on the respiratory-gas channel 13. The agent delivery location 31 maybe located such that the general flow of gas from the expired-gas orifice 25 to the patient end 16 passes by the agent delivery location 31.
[0014] A ventilator 85 may be provided in pneumatic communication with the respiratory gas channel 13. Herein, references to "ventilator" are intended to include devices that provide a force intended to move respiratory gas into a patient via the respiratory gas channel 13. This definition is intended to include devices commonly referred to as a "respirator," as well as devices commonly referred to as a "ventilator." A
portion of the ventilator 85, such as a flexible diaphragm or accordion sleeve, may be moved so as to force therapeutic agent in the respiratory-gas channel 13 into the respiratory system.
[0015] The ventilator 85 may be in pneumatic communication with an expiratory reservoir 52. The expiratory reservoir 52 may serve to provide an area where gas having therapeutic agent may be stored for future inspiration by the patient.
[0016] Figure 2 is a schematic of an embodiment of the delivery device 10 having a first channel 37 from the respiratory-gas channel 13 to the aerosol generator 28, and a second channel 40 from the aerosol generator 28 to the respiratory-gas channel 13. A
pump 43 may be provided within this circuit in order to move gas from the respiratory-gas channel 13, through the aerosol generator 28, and back to the respiratory gas channel 13.
[0017] The embodiment of Figure 2 shows an outlet valve 55 at an end of the expiration reservoir 52. The outlet valve 55 may serve to reduce loss of therapeutic agent from the delivery device 10. The outlet valve 55 may be set to release gas during expiration.
The outlet valve 55 may be set so as to keep a pressure inside the delivery device 10 within an acceptable range.
[0018] Figure 3 is a schematic of another embodiment of a delivery device 10 according to the invention. In this delivery device 10, a bias-gas channel 46 is provided in pneumatic communication with the respiratory-gas channel 13. A bias gas source 49 may supply bias gas via the bias-gas channel 46 to the respiratory-gas channel 13.
The bias gas may be intended to maintain the partial pressure of oxygen desired for the patient.
[0019] Figure 4 shows the bias-gas source 49 and the bias-gas channel 46 located in a different location from that shown in Figure 3. The bias-gas channel 46 is shown in pneumatic communication with an expiratory reservoir 52, which may be similar to that described above.
[0020] Figure 5 is a schematic of a delivery device 10 in which the scrubber housing 22 has a treated-gas orifice 73 and the delivery device 10 includes a treated-gas channel 76 situated so as to provide pneumatic communication between the treated-gas orifice 73 and the respiratory-gas channel 13. The area 88 identifies a portion of the device 10 that is referred to as a "circle circuit", so called because there is a pathway along which gas might flow in a circular fashion. An inspiration check valve 79 may be provided in the circle circuit 88, for example near an end of the treated-gas channel 76. The inspiration check valve 79 may be oriented to open during inspiration and close during expiration. The inspiration check valve 79 may be positioned and oriented so as to prevent incompletely scrubbed gas from re-entering the respiratory-gas channel, which might otherwise occur during inspiration, to encourage particulate therapeutic agent in the respiratory-gas channel 13 to flow generally toward the patient end 16 during inspiration, encourage treated gas to flow generally away from the expired-gas orifice 25, prevent expired gas from bypassing the scrubber housing 22 during expiration, or any combination of these.
[0021] An expiration check valve 82 may be provided in the circle circuit 88.
The expiration check valve 82 may be oriented to open during expiration and close during inspiration. The expiration check valve 82 may be positioned and oriented so as to prevent incompletely scrubbed gas from re-entering the respiratory-gas channel, which might otherwise occur during inspiration, to encourage particulate therapeutic agent in the respiratory-gas channel 13 to flow generally toward the patient end 16 during inspiration, encourage treated gas to flow generally away from the expired-gas orifice 25, prevent expired gas from bypassing the scrubber housing 22 during expiration, or any combination of these.
[0022] Figures 6 and 7 are schematics of other embodiments of a delivery device 10 according to the invention, which include features previously described herein. In Figures 6 and 7, the scrubber housing 22 is not within the circle circuit 88. In these embodiments, expired gas may enter the scrubber housing 22 via the expired-gas orifice 25 during expiration, and treated gas exits the scrubber housing 22 via the expired gas orifice 25 during inspiration. Like the delivery device 10 depicted in Figure 5, the delivery devices 10 in Figures 6 and 7 may have the inspiration check valve 79 and the expiration check valve 82 positioned and oriented so as to prevent incompletely scrubbed gas from re-entering the respiratory-gas channel, which might otherwise occur during inspiration, to encourage particulate therapeutic agent in the respiratory-gas channel 13 to flow generally toward the patient end 16 during inspiration, encourage treated gas to flow generally away from the expired-gas orifice 25, or any combination of these.
[0023] In a method according to the invention, a particulate therapeutic agent may, be delivered. Figure 8 is a block diagram of one such method. In that method, a patient having a respiratory system may be provided 100. A particulate therapeutic agent may be provided 103 to the respiratory system. The therapeutic agent may be provided 103 by nebulizing the therapeutic agent into a gas that is then provided 103 to the respiratory system. A carbon dioxide scrubber may be provided 106 in pneumatic communication with the respiratory system. Expired gas from the respiratory system may be provided 109 to the scrubber, and may be passed 112 through the scrubber to provide treated gas. The treated gas may be thought of as having a lower partial pressure of CO2 than the expired gas. The treated gas may then be provided 115 to the respiratory system. A ventilator may be provided, and portions of the ventilator may be moved in order to force the therapeutic agent into the respiratory system. The ventilator may or may not be in pneumatic communication with the patient.
[0024] The method may provide a bias flow of elevated oxygen fraction to prevent hypoxia, while maintaining a low rate of bias flow in order to minimize expiratory waste. At a bias (fresh gas) flow of 10% of the normal minute ventilation, it is believed that only about 6% of expiratory flow escapes a circle circuit according to the invention; the remainder is re-breathed. If the particulate therapeutic agent is added during expiration, it is believed that most of the therapeutic agent administered during expiration is inspired during a subsequent breath, thereby eliminating waste of therapeutic agent during the expiration phase. Hypoxia and hypercarbia are averted. No special breathing maneuvers are required, and the patient remains comfortable.
[0025] In a method according to the invention, rebreathing therapeutic agent is used to increase the concentration of the therapeutic agent that is delivered to a patient during inspiration, thereby augmenting both delivery and uptake of the therapeutic agent. This should be contrasted with prior art methods in which rebreathing is used merely to conserve volatile agents and gases during anesthesia. In prior art anesthetic applications, the circle circuit anesthetic concentration is regulated to achieve an alveolar gas concentration desired for anesthesia. In such an anesthetic application, lowering the bias flow reduces the quantity of anesthetic agent required for anesthesia, and is not used to raise the concentration of therapeutic agent in order to enhance uptake by the lungs.
[0026] The invention should substantially increase the opportunity for pulmonary absorption of a given amount of therapeutic agent, unless the scrubber or rebreathing circuit removes a large amount of therapeutic agent. To assess the extent to which a rebreathing circuit might remove a therapeutic agent administered as a fine particulate aerosol, we measured the rate of loss of cigarette smoke, which is a fine particulate aerosol, from a soda lime circle circuit. We found that only 11 % to 13% of particulate smoke was consumed by the circuit in 3 seconds, the approximate duration of one respiratory cycle.
Since the rate of removal of a fine particulate aerosol by the rebreather circuit appears to be low, substantial efficiency should be gained by rebreathing particulate therapeutic agents through a carbon dioxide scrubber. In addition, we have found that by administering smoke into a rebreathing circuit, the concentration of smoke in the air delivered to a model lung was increased seven fold.
[0027] A method according to the invention may require little or no patient cooperation. In theory, a method according to the invention may be more efficient than prior art methods of delivering therapeutic agents, and therefore may be more cost effective.
Further, a method according to the invention may be used during prolonged dosing of both spontaneously breathing patients and mechanically ventilated patients.
[0028] Non-rebreathing aerosol administration is safe for the patient breathing room air. However, the rebreathing method described in this application might not be used safely without an elevated fraction of inspired oxygen. Therefore, the method maybe limited to patients having access to oxygen or to oxygen enriched gas mixtures.

[00291 Although the present invention has been described with respect to one or more particular embodiments, it will be understood that other embodiments of the present invention may be made without departing from the spirit and scope of the present invention.
Hence, the present invention is deemed limited only by the appended claims and the reasonable interpretation thereof.

Claims (19)

What is claimed is:
1. A particulate therapeutic agent delivery device comprising:
a respiratory-gas channel having a patient end suitable for pneumatic connection to a patient;
a particulate-therapeutic-agent channel in pneumatic communication with the respiratory-gas channel;
a scrubber housing in pneumatic communication with the respiratory-gas channel, the scrubber housing having an expired-gas orifice for receiving expired gas and particulate therapeutic agent from the respiratory-gas-channel; and a scrubber material situated within the housing so as to receive expired gas and particulate therapeutic agent via the expired-gas orifice and remove carbon dioxide from the expired gas to provide treated gas, and situated so as to provide the treated gas and particulate therapeutic agent to the respiratory-gas channel; and an aerosol generator in pneumatic communication with the particulate-therapeutic-agent channel.
2. The delivery device of claim 1, wherein the particulate-therapeutic agent channel is in pneumatic communication with an agent delivery location on the respiratory-gas channel, the agent delivery location being located so that a general flow of gas from the expired-gas orifice to the patient end passes by the agent delivery location.
3. The delivery device of claim 1, wherein the aerosol generator is a nebulizer.
4. The delivery device of claim 1, further comprising a first channel from the respiratory-gas channel to the aerosol generator, and a second channel from the aerosol generator to the respiratory-gas channel.
5. The delivery device of claim 1, wherein the scrubber housing includes an electrically conductive material.
6. The delivery device of claim 1, wherein the scrubber material is soda-lime.
7. The delivery device of claim 1, wherein the scrubber housing has a treated-gas orifice, and the delivery device further comprises a treated-gas channel situated so as to provide pneumatic communication between the treated-gas orifice and the respiratory-gas channel, so that gas that has past through the scrubber housing is delivered to the respiratory-gas channel.
8. The delivery device of claim 1, further comprising a check valve positioned and oriented in the delivery device to encourage particulate therapeutic agent in the respiratory-gas channel to flow generally toward the patient end during inspiration.
9. The delivery device of claim 1, further comprising a check valve positioned and oriented in the delivery device to prevent expired gas from bypassing the scrubber housing during expiration.
10. The delivery device of claim 1, further comprising a ventilator in pneumatic communication with the respiratory-gas channel.
11. The delivery device of claim 1, wherein the particulate-therapeutic-agent channel has therein a particulate therapeutic agent.
12. The delivery device of claim 11, wherein the particulate therapeutic agent is a liquid.
13. The delivery device of claim 11, wherein the particulate therapeutic agent is a solid.
14. Use of a delivery device for gas treatment of a patient with a particulate therapeutic agent, the delivery device comprising a carbon dioxide scrubber suitable for pneumatic communication with a respiratory system of the patient and an aerosol generator suitable for providing the particulate therapeutic agent to the patient, wherein the delivery device is suitable for providing expired gas from the respiratory system to the scrubber, passing the expired gas through the scrubber to provide treated gas, the treated gas suitable for delivery to the respiratory system, and wherein the particulate therapeutic agent is present in the treated gas.
15. The use of claim 14, wherein the delivery device further comprises a ventilator suitable for forcing the treated gas comprising the therapeutic agent into the respiratory system.
16. The use of claim 14, wherein the therapeutic agent is nebulized.
17. The use of claim 14, wherein the particulate therapeutic agent is a liquid.
18. The use of claim 14, wherein the particulate therapeutic agent is a solid.
19. Use of the delivery device of any one of claims 1- 13 for gas treatment of a patient with a particulate therapeutic agent.
CA2490857A 2002-06-28 2003-06-30 Particulate therapeutic agent delivery device and method Expired - Fee Related CA2490857C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39231402P 2002-06-28 2002-06-28
US60/392,314 2002-06-28
PCT/US2003/020532 WO2004002390A2 (en) 2002-06-28 2003-06-30 Therapeutic agent delivery device and method

Publications (2)

Publication Number Publication Date
CA2490857A1 CA2490857A1 (en) 2004-01-08
CA2490857C true CA2490857C (en) 2011-08-30

Family

ID=30000843

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2490857A Expired - Fee Related CA2490857C (en) 2002-06-28 2003-06-30 Particulate therapeutic agent delivery device and method

Country Status (9)

Country Link
US (1) US7367335B2 (en)
EP (2) EP3335752A1 (en)
JP (1) JP2005531373A (en)
AU (1) AU2003247834A1 (en)
CA (1) CA2490857C (en)
ES (1) ES2651342T3 (en)
HK (1) HK1254943A1 (en)
MX (1) MXPA05000223A (en)
WO (1) WO2004002390A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7089933B2 (en) * 2002-10-25 2006-08-15 Hamilton Sundstrand CO2 sorbent for inhalation drug therapy system
US7849853B2 (en) * 2003-02-11 2010-12-14 Trudell Medical International Ventilator circuit and the method for the use thereof
US8028697B2 (en) * 2005-04-28 2011-10-04 Trudell Medical International Ventilator circuit and method for the use thereof
KR102103541B1 (en) * 2005-08-12 2020-04-23 캄브리오스 필름 솔루션스 코포레이션 Nanowires-based transparent conductors
WO2007133837A2 (en) * 2006-05-12 2007-11-22 Advanced Technology Materials, Inc. Low temperature deposition of phase change memory materials
JP5307715B2 (en) 2006-08-21 2013-10-02 トルーデル メディカル インターナショナル Respiratory muscle endurance training equipment
FR2906710B1 (en) * 2006-10-05 2008-12-12 Equip Veterinaire Minerve Sa SAFETY ANESTHESIA DEVICE FOR MEDICAL SAMPLES CARRIED OUT WITH HIGH CADENCE ON SMALL LABORATORY ANIMALS
FR2915106B3 (en) * 2007-04-18 2009-03-06 Diffusion Tech Francaise Sarl PNEUMATIC NEBULIZER DEVICE OF AEROSOLS.
US8151794B2 (en) 2007-04-24 2012-04-10 Trudell Medical International Aerosol delivery system
WO2008138014A1 (en) * 2007-05-08 2008-11-13 The Research Foundation Of State University Of New York Breathing-gas delivery system with exhaust gas filter body and method of operating a breathing-gas delivery system
EP2008679A1 (en) * 2007-06-28 2008-12-31 General Electric Company Patient breathing system
WO2009105515A2 (en) 2008-02-21 2009-08-27 Trudell Medical International Respiratory muscle endurance training device and method for the use thereof
WO2010036816A1 (en) 2008-09-25 2010-04-01 Nellcor Puritan Bennett Llc Inversion-based feed-forward compensation of inspiratory trigger dynamics in medical ventilators
US8596265B2 (en) 2008-10-22 2013-12-03 Trudell Medical International Modular aerosol delivery system
US20120318263A1 (en) * 2011-06-16 2012-12-20 General Electric Company Anesthesia vaporizer system and method
SG10201601960SA (en) * 2011-09-14 2016-04-28 American Regenerative Technologies Llc Inhalation systems, breathing apparatuses, and methods
WO2013166430A2 (en) * 2012-05-04 2013-11-07 Trustees Of The University Of Pennsylvania System for delivery of gaseous imaging contrast agents and methods for using same
EP4186548A1 (en) 2015-04-02 2023-05-31 Hill-Rom Services PTE. LTD. Mask leakage detection for a respiratory device
CA2990545A1 (en) * 2015-07-06 2017-01-12 Joel Ironstone Oxygen rebreathing apparatus and method for using the same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1693730A (en) * 1925-11-16 1928-12-04 Elfriede Drager Breathing apparatus particularly for administering anesthetics
DE1251913B (en) 1965-03-20 1967-10-12 Dragerwerk Hemr & Bernh Drager, Lübeck Ventilation device
US4127121A (en) * 1976-09-17 1978-11-28 University Of Utah Oxygen and anesthesia delivery and monitoring device
US4354536A (en) 1980-04-09 1982-10-19 Jack Moss Gasoline dispensing nozzle
US4466433A (en) 1981-12-04 1984-08-21 Minnesota Mining And Manufacturing Company Overpressure relief system
JPS59101159A (en) 1982-11-30 1984-06-11 泉工医科工業株式会社 Artificial respirator having double-barreled jet pipe
US4821709A (en) 1983-08-01 1989-04-18 Sensormedics Corporation High frequency ventilator and method
DE3429389C1 (en) 1984-08-09 1986-03-13 Brugger, Inge, geb. Ritzau, 8130 Starnberg Inhaler
SE451051B (en) 1985-03-26 1987-08-31 Icor Ab DEVICE FOR Saturation of a person's acid uptake
US4719910A (en) 1985-04-29 1988-01-19 Jensen Robert L Oscillating ventilator and method
US4805612A (en) 1985-09-13 1989-02-21 Sensormedics Corporation High frequency ventilation
US4879996A (en) 1987-01-13 1989-11-14 Harwood Jr Van N Closed circuit breathing apparatus
SE8700977D0 (en) * 1987-03-09 1987-03-09 Olof Werner UNIT WHICH SEPARATELY SEPARATES THE GAS CONTENT IN THE DRIVE CIRCUIT AND THE RECEIVER CIRCUIT BUT ONLY ALLOWS GAS PIPE IN THE BAD DIRECTIONS (OPEN SEPARATION)
US5322057A (en) * 1987-07-08 1994-06-21 Vortran Medical Technology, Inc. Intermittent signal actuated nebulizer synchronized to operate in the exhalation phase, and its method of use
JPS6449541A (en) 1987-08-19 1989-02-27 Anzai Sogyo Co Ltd Xenon gas inhalation system
US5092326A (en) 1987-11-19 1992-03-03 Winn Bryan D Apparatus and method for a ventilator system
US4951659A (en) 1988-11-04 1990-08-28 Automatic Liquid Packaging, Inc. Nebulizer with cooperating disengageable on-line heater
SE465497B (en) 1989-11-24 1991-09-23 Minco Ab DEVICE FOR STUDYING A PERSON'S LUNG FUNCTION
US5165398A (en) 1989-12-08 1992-11-24 Bird F M Ventilator and oscillator for use therewith and method
AU657726B2 (en) * 1990-12-05 1995-03-23 General Hospital Corporation, The Devices for treating pulmonary vasoconstriction and asthma
US5570683A (en) * 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5186166A (en) * 1992-03-04 1993-02-16 Riggs John H Powder nebulizer apparatus and method of nebulization
US5307794A (en) 1992-04-01 1994-05-03 Sensormedics Corporation Oscillating ventilator apparatus and method and patient isolation apparatus
US5335650A (en) * 1992-10-13 1994-08-09 Temple University - Of The Commonwealth System Of Higher Education Process control for liquid ventilation and related procedures
US5555880A (en) 1994-01-31 1996-09-17 Southwest Research Institute High frequency oscillatory ventilator and respiratory measurement system
US5590651A (en) * 1995-01-17 1997-01-07 Temple University - Of The Commonwealth System Of Higher Education Breathable liquid elimination analysis
SE9500175L (en) 1995-01-19 1996-07-20 Siemens Elema Ab Method and apparatus for identifying at least one anesthetic in an anesthetic device
US5823180A (en) * 1995-04-03 1998-10-20 The General Hospital Corporation Methods for treating pulmonary vasoconstriction and asthma
SE9503141D0 (en) * 1995-09-12 1995-09-12 Siemens Elema Ab Anesthesia apparatus
RU2072241C1 (en) * 1995-09-20 1997-01-27 Панина Елена Владимировна Method and device for preparing inhalation gas mixture
SE9503665L (en) 1995-10-19 1997-04-20 Siemens Elema Ab Anesthesia System
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
JP3898251B2 (en) 1996-03-28 2007-03-28 スズキ株式会社 Diaphragm neutral position controller for ventilator
US6095135A (en) * 1998-07-10 2000-08-01 Enternet Medical, Inc. Apparatus for providing benefits to respiratory gases
SE9902627D0 (en) * 1999-07-08 1999-07-08 Siemens Elema Ab Medical nebulizer

Also Published As

Publication number Publication date
US7367335B2 (en) 2008-05-06
CA2490857A1 (en) 2004-01-08
AU2003247834A1 (en) 2004-01-19
US20040003808A1 (en) 2004-01-08
EP1558312A2 (en) 2005-08-03
HK1254943A1 (en) 2019-08-02
MXPA05000223A (en) 2005-07-15
ES2651342T3 (en) 2018-01-25
EP1558312B1 (en) 2017-08-09
WO2004002390A3 (en) 2004-04-29
EP1558312A4 (en) 2010-01-20
EP3335752A1 (en) 2018-06-20
JP2005531373A (en) 2005-10-20
AU2003247834A8 (en) 2004-01-19
WO2004002390A2 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
CA2490857C (en) Particulate therapeutic agent delivery device and method
US6694973B1 (en) Nasal mask for use in intermittent positive pressure ventilation therapy
US6019100A (en) Ventilator device
US20030145853A1 (en) Expiration- dependent gas dosage
JP6640832B2 (en) Positive pressure inhaler for drug delivery
JP2000501306A (en) Method and apparatus for closed circuit ventilation therapy
KR20010005502A (en) Elimination of vapour anaesthetics from patients after surgical procedures
US11707593B2 (en) Sedation device
US7533669B2 (en) Gas delivery system and method
BARZILAY et al. Traumatic respiratory insufficiency: comparison of conventional mechanical ventilation to high-frequency positive pressure with low-rate ventilation
CA2540531C (en) Device and method of partially separating gas
JPH08317981A (en) Oxygen supply apparatus regulatable of oxygen concentration to spontaneously respirable patient using tracheal tube or mask
CN2627861Y (en) Oxygen taking and toxin removing mask according to requirement
RU2102068C1 (en) Method of xenon anesthesia carrying out by endotracheal type
JP2005342353A (en) Inhalator and inhalation apparatus, or method for applying inhalator
JP3245439U (en) medical atomization device
CN213077084U (en) Oxygen storage mask combined atomization inhalation device
JPH11197246A (en) Intermittently positive pressure type respiratory assisting device
CN209378230U (en) Physiotherapy device for department of respiration
JP5255430B2 (en) Device for administering pharmaceutical products in aerosol form
JPH08224321A (en) Oxygen can containing carbon dioxide
BARAKA et al. Automatic jet ventilation in children anaesthetized by the T‐piece circuit
JP2000102617A (en) Positive pressure artificial respiratory auxiliary apparatus
CN111603640A (en) Medicine inhalation auxiliary device
WO2020120212A1 (en) Humidification and mucus mobilization with an on-demand humidifier

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831